Lupin partners with Sandoz to market, commercialize Ranibizumab biosimilar across multiple regions
Lupin will be responsible for manufacturing the product and for regulatory submissions.
Mumbai: Global Pharma major Lupin Limited has announced that it has partnered with Sandoz Group AG, Switzerland, to market and commercialize Lupin's biosimilar ranibizumab across multiple regions.
Under the terms of the agreement, Sandoz will oversee commercialization of the product across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia.
Lupin will be responsible for manufacturing the product and for regulatory submissions. Sandoz will hold exclusive marketing rights in most of the designated markets, except for France, Australia, Vietnam, and Malaysia, where it will have semi-exclusive marketing rights.
Pursuant to another agreement executed between the two companies, Sandoz will acquire sole rights for commercialization of Lupin’s biosimilar ranibizumab in Canada, while Lupin will manage its manufacture and regulatory filings.
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). Its indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Proliferative Diabetic Retinopathy (PDR), and Choroidal Neovascularization (CNV).
“We are delighted to partner with Sandoz for the launch and commercialization of ranibizumab in multiple markets globally,” said Thierry Volle, President EMEA and Emerging Markets, Lupin. “This partnership underscores our shared vision to expand global access to cutting-edge biologic therapies and improve outcomes for underserved patients.”
Lupin Limited is a global pharmaceutical company headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company has a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally.
Next Story